Keywords
Lipotoxicity
Cytokines
Obesity
Chronic kidney disease
Cardiovascular disease
How to Cite
Abstract
Background: Obesity is a systemic disease that has been underrecognized for years. Obesity-associated chronic kidney disease (Ob-CKD) is a multifaceted disorder affecting patients with varying degrees of obesity. This condition arises through both direct and indirect mechanisms, and these patients have an increased risk of developing cardiovascular disease (CVD) with its different manifestations, including coronary artery disease, heart failure (HF), arrhythmias, and sudden cardiac death. There is a complex interaction between obesity, chronic kidney disease (CKD), and the development of cardiac involvement. In recent years, there has been increasing interest in understanding the role of obesity in the development of CKD and heart f failure.
Purpose: Analyze the pathophysiological mechanisms involved in the development of obesity-related kidney disease and heart failure and their possible interactions from the perspective of inflammation and lipotoxicity.
Methodology: A narrative review was conducted using various databases, employing keywords to identify the best available evidence on inflammation and lipotoxicity as factors related to cardiorenal dysfunction in people with obesity.
Results: This review was structured using articles in English and Spanish.
Conclusions: In the pathophysiology of obesity associated with cardiorenal involvement, there are several axes of progression, one of which is adipocyte dysfunction. The cardiorenal interaction is complex, and inflammation and lipotoxicity play a central role. Understanding the processes involved opens new possibilities for therapeutic interventions.
References
Nawaz S, Chinnadurai R, Al?Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: a current review. Obes Sci Pract. 2022;9(2):61-74. https://doi.org/10.1002/osp4.629
Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol. 2014;25(9):2088-96. https://doi.org/10.1681/asn.2013070754
Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl. 2017;7(2):122-9. https://doi.org/10.1016/j.kisu.2017.07.007
Hojs R, Ekart R, Bevc S, Vodošek Hojs N. Chronic kidney disease and obesity. Nephron. 2023;147(11):660-4. https://doi.org/10.1159/000531379
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157-72. https://doi.org/10.1161/circulationaha.120.050686
Schuett K, Marx N, Lehrke M. The cardio-kidney patient: epidemiology, clinical characteristics and therapy. Circ Res. 2023;132(8):902-14. https://doi.org/10.1161/circresaha.122.321748
Chen X, Ruiz-Velasco A, Zou Z, Hille SS, Ross C, Fonseka O, et al. PAK3 exacerbates cardiac lipotoxicity via SREBP1c in obesity cardiomyopathy. Diabetes. 2024;73(11):1805-20. https://doi.org/10.2337/db24-0240
Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024;84(17):1587-602. https://doi.org/10.1016/j.jacc.2024.08.021
Cases A, Broseta JJ, Marqués M, Cigarrán S, Julián JC, Alcázar R, et al. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología. Nefrología. 2024;44(6):769-920. https://www.revistanefrologia.com/es-la-definicion-del-sindrome-cardiovascular-reno-metabolico-articulo-S0211699524000365
Rico-Fontalvo J, Daza-Arnedo R, Montejo-Hernandez J, Cardona-Blanco M, Rodríguez-Yanez T. Reflexiones de la enfermedad renal crónica asociada a obesidad: de una vieja relación causal hasta un enfoque basado en la fenotipificación. Rev Soc Ecuat Nefrol Diálisis Traspl. 2022;10(2):137-9. https://doi.org/10.56867/37
León-Román J, López-Martínez M, Esteves A, Ciudin A, Núñez-Delgado S, Álvarez T, et al. Obesity-related kidney disease: a growing threat to renal health. Int J Mol Sci. 2025;26(14):6641. https://doi.org/10.3390/ijms26146641
Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-33. https://doi.org/10.1161/01.hyp.0000052314.95497.78
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498-509. https://doi.org/10.1046/j.1523-1755.2001.0590041498.x
Martin-Taboada M, Vila-Bedmar R, Medina-Gómez G. From obesity to chronic kidney disease: how can adipose tissue affect renal function? Nephron. 2021;145(6):609-13. https://doi.org/10.1159/000515418
Tobar A, Ori Y, Benchetrit S, Milo G, Herman-Edelstein M, Zingerman B, et al. Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PloS One. 2013;8(9):e75547. https://doi.org/10.1371/journal.pone.0075547
Chen Y, Dabbas W, Gangemi A, Benedetti E, Lash J, Finn PW, et al. Obesity management and chronic kidney disease. Semin Nephrol. 2021;41(4):392-402. https://doi.org/10.1016/j.semnephrol.2021.06.010
Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab. 2014;28(1):71-9. https://doi.org/10.1016/j.beem.2013.08.002
Rico-Fontalvo J, Ciudin A, Correa-Rotter R, Díaz-Crespo FJ, Bonanno C, Lecube A, et al. SEN, SLANH, and SEEDO Consensus report on Obesity related kidney disease. Proposal for a new classification. Kidney Int. 2025;108(4):572-83. https://doi.org/10.1016/j.kint.2025.06.013
Ren L, Cui H, Wang Y, Ju F, Cai Y, Gang X, et al. The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomed Pharmacother. 2023;161:114465. https://doi.org/10.1016/j.biopha.2023.114465
Rico-Fontalvo J, Daza-Arnedo R, Rodriguez-Yanez T, Martinez-Avila MC, Cabrales J, Cardona-Blanco MX, et al. Inflammation and diabetic kidney disease: new perspectives. J Biomed Res Environ Sci. 2022;3(7):779-86. https://doi.org/10.37871/jbres1513
Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14(2):105-20. https://doi.org/10.1038/nrneph.2017.157
Schelling JR. The contribution of lipotoxicity to diabetic kidney disease. Cells. 2022;11(20):3236. https://doi.org/10.3390/cells11203236
Garbarino J, Sturley SL. Saturated with fat: new perspectives on lipotoxicity. Curr Opin Clin Nutr Metab Care. 2009;12(2):110-6. https://doi.org/10.1097/mco.0b013e32832182ee
Zbrze?niak-Suszczewicz J, Winiarska A, Perkowska-Ptasi?ska A, Stompór T. Obesity-related glomerulosclerosis—how adiposity damages the kidneys. Int J Mol Sci. 2025;26(13):6247. https://doi.org/10.3390/ijms26136247
Fazeli SA, Nourollahi S, Alirezaei A, Mirhashemi S, Davarian A, Hosseini I. Perirenal adipose tissue: clinical implication and therapeutic interventions. Indian J Nephrol. 2024;34(6):573-82. https://doi.org/10.25259/ijn_532_23
D’Marco L, Salazar J, Cortez M, Salazar M, Wettel M, Lima-Martínez M, et al. Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease. Kidney Res Clin Pract. 2019;38(3):365-72. https://doi.org/10.23876/j.krcp.18.0155
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1-2):24-30. https://doi.org/10.1016/j.cca.2007.01.026
Vilariño-García T, Polonio-González ML, Pérez-Pérez A, Ribalta J, Arrieta F, Aguilar M, et al. Role of leptin in obesity, cardiovascular disease, and type 2 diabetes. Int J Mol Sci. 2024;25(4):2338. https://doi.org/10.3390/ijms25042338
Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789-806. https://doi.org/10.1161/circresaha.119.312321
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606-35. https://doi.org/10.1161/cir.0000000000001184
Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31(2):544-51. https://doi.org/10.1038/s41591-024-03374-z
Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283-96. https://doi.org/10.1111/dom.14829
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-88. https://doi.org/10.1152/physrev.00045.2011
Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144-53. https://doi.org/10.1038/nrendo.2015.216
Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA, et al. Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721-35. https://doi.org/10.1016/j.jacc.2025.03.009
Chen Y, Wu S, Liu H, Zhong Z, Bucci T, Wang Y, et al. Role of oxidative balance score in staging and mortality risk of cardiovascular-kidney-metabolic syndrome: Insights from traditional and machine learning approaches. Redox Biol. 2025;81:103588. https://doi.org/10.1016/j.redox.2025.103588
Boorsma EM, Ter Maaten JM, Damman K, van Essen BJ, Zannad F, van Veldhuisen DJ, et al. Albuminuria as a marker of systemic congestion in patients with heart failure. Eur Heart J. 2023;44(5):368-80. https://doi.org/10.1093/eurheartj/ehac528
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.